First-Line treatment with pembrolizumab doubled five-year survival rate vs chemotherapy in certain patients with metastatic non-small cell lung cancer whose tumours express PD-L1

Results from phase 3 KEYNOTE-024 trial (n=305) showed the overall survival rate was twice as high for patients who received pembrolizumab (31.9%; n=154) versus chemotherapy alone (16.3%; n=151).

Source:

Biospace Inc.